Patents Issued in December 8, 2020
-
Patent number: 10857163Abstract: The invention provides compositions containing isomerically pure forms of neurosteroids that permit preferential modulation of different subtypes of GABAA receptors, such as preferential modulation of ?4?3? GABAA receptors over ?1?2?2 GABAA receptors. The invention also provides methods of treating GABAA disorders using such compositions.Type: GrantFiled: September 30, 2019Date of Patent: December 8, 2020Assignee: ATHENEN THERAPEUTICS, INC.Inventors: Andrew D. Levin, Neil Buckley
-
Patent number: 10857164Abstract: The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhoea and C. difficile associated colitis.Type: GrantFiled: October 1, 2019Date of Patent: December 8, 2020Assignee: UNION therapeutics A/SInventors: Morten Otto Alexander Sommer, Ramus Vendler Toft-Kehler, Daniel Jean Jacques Simon
-
Patent number: 10857165Abstract: Disclosed herein are methods and compositions for removing or displacing bisphosphonates in skeletal tissue.Type: GrantFiled: May 31, 2017Date of Patent: December 8, 2020Assignees: The Regents of the University of California, BioVinc LLC, University of Southern CaliforniaInventors: Frank Hallock Ebetino, Ichiro Nishimura, Shuting Sun, Mark Walden Lundy, Akishige Hokugo, Charles McKenna, Keivan Sadrerafi
-
Patent number: 10857166Abstract: Flavonoids that are isolated from plant material of the genus Cecropia can be used to perturb G-protein coupled receptors in a mammalian cell. In some instances, one or more flavonoids may interact with one or more of the G-protein coupled receptors to transiently increase the concentration of cytosolic calcium. Administration of the isolated flavonoids can be used to treat hypertension, to protect the integrity of blood vessels and related conditions.Type: GrantFiled: January 30, 2018Date of Patent: December 8, 2020Assignee: INSTITUTO DE INVESTIGACIONES CIENTIFICAS Y SERVICIOS DE ALTA TECNOLOGIA (INDICASAT AIP)Inventors: Catherina C. Caballero-George, Andres Rivera Mondragon
-
Patent number: 10857167Abstract: Provided herein are compositions and methods related to use of oligosaccharides, such as 2?-fucosyllactose, for increasing weight gain in a subject. In some aspects the compositions and methods are for use in infants, such as premature infants or infants having intestinal failure.Type: GrantFiled: April 28, 2016Date of Patent: December 8, 2020Assignee: CHILDREN'S HOSPITAL MEDICAL CENTERInventors: Ardythe L. Morrow, Michael A. Helmrath, Ethan Mezoff
-
Patent number: 10857168Abstract: This invention relates to a method and composition for modulating the microbiota in the gastro-intestinal tracts of non-infant humans who are carriers of the human fucosyltransferase 2 (FUT2) genetic mutation.Type: GrantFiled: February 24, 2017Date of Patent: December 8, 2020Assignee: GLYCOM A/SInventors: Bruce McConnell, Louise Kristine Vigsnæs
-
Patent number: 10857169Abstract: Powder formulations for inhalation which comprise microparticles containing an antibiotic and magnesium stearate are useful for the treatment of bacterial infections associated with certain pulmonary diseases.Type: GrantFiled: December 14, 2010Date of Patent: December 8, 2020Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: David Morton, Qi Zhou, Rossella Musa
-
Patent number: 10857170Abstract: A SIRT6 activating molecule as shown in Tables 1-3 or a compound according to a pharmacophore as described herein.Type: GrantFiled: December 30, 2016Date of Patent: December 8, 2020Assignee: SirTLab CorporationInventors: Haim Yosef Cohen, Yariv Kanfi
-
Patent number: 10857171Abstract: The stable pharmaceutical compositions comprising a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof are disclosed.Type: GrantFiled: January 12, 2017Date of Patent: December 8, 2020Assignee: WOCKHARDT LIMITEDInventors: Mohammad Ajmal Shareef, Mrutunjaya Sahu, Ajaykumar Handa
-
Patent number: 10857172Abstract: Methods for delivering at least one compound selected from nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, in combination with at least one of thiamine (vitamin B1), riboflavin (vitamin B2), niacin (vitamin B3), and pyridoxine (vitamin B6), to an infant human subject in need of said compound or compounds are provided.Type: GrantFiled: April 14, 2017Date of Patent: December 8, 2020Assignee: ChromaDex, Inc.Inventors: Ryan Dellinger, Troy Rhonemus, Mark Morris, Dietrich Conze, Amy Boileau
-
Patent number: 10857173Abstract: The present invention provides methods for treating or suppressing tumor metastasis at a site distinct from the bladder in an individual having a urothelial carcinoma of lower tract, comprising locally delivering to the bladder an effective amount of a chemotherapeutic agent (such as gemcitabine), wherein the chemotherapeutic agent is delivered continuously to the bladder for a sustained period of time (such as at least 24 hours).Type: GrantFiled: July 25, 2018Date of Patent: December 8, 2020Assignee: TARIS Biomedical LLCInventor: Dennis Giesing
-
Patent number: 10857174Abstract: Disclosed are morpholino oligonucleotides that can be used to silence expression of MGMT, pharmaceutical compositions that include said morpholino oligonucleotides, and methods of using said morpholino oligonucleotides in the treatment of cancer, particularly methods that involve the use of radiation to deliver said morpholino oligonucleotides.Type: GrantFiled: July 25, 2019Date of Patent: December 8, 2020Assignees: UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, OREGON HEALTH & SCIENCE UNIVERSITYInventors: Prakash Ambady, Jeffrey Wu, Edward Neuwelt
-
Patent number: 10857175Abstract: The application describes compositions that include maltosyl-isomalto-oligosaccharides with a desirable mass average molecular weight distribution. In some cases, the compositions can contain at least 3% mannitol.Type: GrantFiled: February 13, 2020Date of Patent: December 8, 2020Assignee: ISOThrive Inc.Inventors: Lee Madsen, II, Jack Oswald
-
Patent number: 10857176Abstract: The present disclosure relates to a method which allows direct formation of gel-like solutions of polyglucosamine at neutral pH?7 to 8, eliminating the need of prior dissolution of polyglucosamine in acidic environment; and to a homogeneous liquid combination of polyglucosamine-glyoxylate with hyaluronan.Type: GrantFiled: April 25, 2019Date of Patent: December 8, 2020Inventors: Amine Selmani, Abdellatif Chenite
-
Patent number: 10857177Abstract: The invention provides various isolated and synthetic forms of lipidated PSA as well as isolated or synthetic forms of the glycolipid component of lipidated PSA, and compositions thereof, methods of making including methods of isolating such forms, and methods of use thereof.Type: GrantFiled: August 19, 2016Date of Patent: December 8, 2020Assignee: President and Fellows of Harvard CollegeInventors: Sungwhan Oh, Deniz Erturk-Hasdemir, Dennis L. Kasper
-
Patent number: 10857178Abstract: Cerium oxide nanoparticles (CeONP) can be used to treat or prevent neurodegenerative diseases, including for example Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, AIDS-related dementia, ALS, progressive supranuclear palsy, and encephalitis, as well as mitochondrial diseases and diseases associated with mitochondrial damage. In particular, CeONP having an average size of about 2 nm to about 100 nm can be administered in an amount sufficient to block production of hydroxyl or superoxide radicals, block free radical production by A?(1-42), block A?(1-42)-induced neuronal death, block A?(1-42)-induced [Ca2+]i dysfunction in neurons, block A?(1-42)-induced lipid peroxidation, decrease loss of dopaminergic neurotransmission, or reduce mitochondrial dysfunction in a cell.Type: GrantFiled: October 16, 2008Date of Patent: December 8, 2020Assignee: EDWARD VIA VIRGINIA COLLEGE OF OSTEOPATHIC MEDICINEInventors: Beverly A. Rzigalinski, Neeraj Singh, Courtney A. Cohen
-
Patent number: 10857179Abstract: The invention concerns a mixture or a composition, that is preferably therapeutically active by topical administration, comprising: —at least one metal salt, the metal being chosen from molybdenum (Mo), tungsten (W), vanadium (V), gold (Au), a lanthanide, in particular lanthanum; —at least one chelating agent; —at least one source of peroxidative radicals; —at least one buffer agent; and pharmaceutical compositions constituted by or comprising said mixture, the methods for producing same and applications thereof, in particular in a method for the therapeutic treatment of a viral infection, and in particular involving a virus of the Herpesviridae family; or as an anti-inflammatory.Type: GrantFiled: March 29, 2017Date of Patent: December 8, 2020Assignee: OXYMO TECHNOLOGIES INC.Inventors: Rémi Wilmotte, Frédéric Lorenzo, Denis Olivier Chretien
-
Patent number: 10857180Abstract: A pharmaceutical composition of the present invention is used for improving health, cure abnormalities and degenerative disease; achieve anti-aging effect of therapy and therapeutic effect on mammals. The pharmaceutical composition includes a pharmaceutical carrier and an isotope selective ingredient including at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100%. A method of the present invention uses the inventive pharmaceutical composition to improve health, cure abnormalities and degenerative disease and achieve therapeutic effect on mammals.Type: GrantFiled: December 29, 2018Date of Patent: December 8, 2020Assignee: Vector Vitale IP LLCInventors: Peter Y Novak, Maxim V Temnikov, Oleksandr Balakin
-
Patent number: 10857181Abstract: Cell preparations comprising a pooled and enriched, mononuclear apoptotic cell population, and a method of preparing this cell preparation are described. The pooled mononuclear apoptotic cell preparation may be obtained from pooled, allogeneic white blood cell fractions that are pooled prior to or following induction of apoptosis. Further, described herein are methods of use of these pooled apoptotic cell preparations for treating an immune disease, an inflammatory disease, an autoimmune disease, or infertility in a subject. For example, a pooled apoptotic cell preparation may be used to treat graft versus host disease (GVHD) in an allogeneic subject.Type: GrantFiled: April 21, 2016Date of Patent: December 8, 2020Assignee: ENLIVEX THERAPEUTICS LTDInventors: Dror Mevorach, Shai Novik
-
Patent number: 10857182Abstract: Provided herein are methods of generating antigen-specific T cells for therapeutic administration to a human patient having or suspected of having a pathogen or cancer, utilizing stem cell-like memory T cells (TSCM cells). Also disclosed are antigen-specific T cells generated by such methods, and methods of treating a human patient using such antigen-specific T cells.Type: GrantFiled: September 22, 2017Date of Patent: December 8, 2020Assignee: Memorial Sloan Kettering Cancer CenterInventors: Richard John O'Reilly, Aisha Nasreen Hasan
-
Patent number: 10857183Abstract: The present disclosure provides distinct therapeutic populations of cells that form a pharmaceutical composition useful in hematopoietic stem/progenitor cell transplant. For example, the present disclosure provides a therapeutic population of cells, comprising an enriched population of hematopoietic stem/progenitor cells, memory T cells, regulatory T cells, and wherein the population of cells is depleted of naïve conventional ??-T cells. The present disclosure further provides methods of treatment using the therapeutic population of cells. In other embodiments, the present disclosure provides methods of producing a therapeutic population of cells.Type: GrantFiled: April 18, 2019Date of Patent: December 8, 2020Assignee: ORCA BIOSYSTEMS, INC.Inventors: Ivan K. Dimov, Nathaniel Fernhoff, Kevin Sheehan
-
Patent number: 10857184Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.Type: GrantFiled: June 6, 2019Date of Patent: December 8, 2020Assignee: CRISPR Therapeutics AGInventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
-
Patent number: 10857185Abstract: Cocktails of chemical inducers of neuron-like properties (CINP) is provided, which includes cAMP agonists, neurogenic small molecules, glycogen synthase kinase inhibitors, TGF? receptor inhibitors, and BET family bromodomain inhibitors and optionally, a selective inhibitor of ROCK or p38 MAPK. These cocktails are used in a method of inducing neuron-like properties in partially or completely differentiated non-neuronal cells. The method includes contacting cells of a first type (non-neuronal) with the CINPs for a sufficient period of time to result in reprogramming the cell into cells of a second type having neuron-like characteristics (CiNs). Isolated chemically induced neurons (CiNs) can be used in a number of applications, including but not limited to cell therapy.Type: GrantFiled: July 1, 2016Date of Patent: December 8, 2020Assignees: Beihao Stem Cell and Regenerative Medicine Research Institutes Co., Ltd., Peking UniversityInventors: Hongkui Deng, Xiang Li, Xiaohan Zuo
-
Patent number: 10857186Abstract: A traditional Chinese medicine composition for treating acute stage of cerebral infarction. The traditional Chinese medicine composition combines buffalo horns, unprocessed rehmannia roots, red paeony roots, cortex moutan, grassleaf sweelflag rhizome and turmeric root-tuber, and exerts the synergistic effects of the medicines through compatibility, thereby being capable of more effectively clearing away heat and toxic materials, cooling the blood, dissipating blood stasis and inducing resuscitation, and achieving the purpose of treating acute stage of cerebral infarction.Type: GrantFiled: March 11, 2020Date of Patent: December 8, 2020Assignee: Jiangsu Province Institute of Traditional Chinese MedicineInventors: Hongquan Liu, Xiaolan Cheng, Jingbo Li, Mingming Fang, Shuting Jiang, Yudi Lu, Jie Gong
-
Patent number: 10857187Abstract: Brain injury can be caused by trauma or may occur in stroke or neurodegenerative diseases. The disclosure relates to compositions that can include exosomes isolated from human adipose-derived stem cells (hASC) and methods where exosomes from hASC may be used alone or in combination with insulin for the treatment of brain injury.Type: GrantFiled: June 18, 2018Date of Patent: December 8, 2020Assignee: University of South FloridaInventors: Niketa A. Patel, Paula Cole Bickford
-
Patent number: 10857188Abstract: In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated travelers diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.Type: GrantFiled: May 9, 2018Date of Patent: December 8, 2020Assignee: Crestovo Holdings LLCInventor: Thomas Julius Borody
-
Patent number: 10857189Abstract: A method for preventing and/or treating vitamin B12 deficiency is taught. The method comprises administering a composition comprising pseudovitamin B12-producing bacteria, optionally in conjunction with mucin-degrading and/or propionate-producing bacteria, to a subject in need thereof. The method is particularly suitable for administration to subjects suffering from vitamin B12 deficiency due to metformin treatment for type-2 diabetes, and to subjects having undergone bariatric surgery.Type: GrantFiled: February 27, 2017Date of Patent: December 8, 2020Assignee: Caelus Pharmaceuticals B.V.Inventor: Willem Meindert De Vos
-
Patent number: 10857190Abstract: Bacterial hyperswarmers are disclosed for treatment, prevention and diagnosis conditions such as intestinal inflammation.Type: GrantFiled: September 21, 2016Date of Patent: December 8, 2020Assignee: Albert Einstein College of MedicineInventors: Sridhar Mani, Libusha Kelly, Hao Li
-
Patent number: 10857191Abstract: Provided herein are methods of using therapeutically effective compositions of sandalwood oil to treat oral mucositis.Type: GrantFiled: October 6, 2016Date of Patent: December 8, 2020Assignee: SANTALIS PHARMACEUTICALS, INC.Inventors: Corey Levenson, Paul Castella, Ian Clements
-
Patent number: 10857192Abstract: This invention relates to the use Pulicaria incisa (Pi) infusion for granting cells and tissues with anti-oxidative effect. The invention further relates to the use Pulicaria incisa (Pi) infusion for treating neuroinflammatory conditions. The invention further relates to cultivated Pi in treating neuroinflammatory conditions and producing anti-oxidative effect.Type: GrantFiled: December 24, 2013Date of Patent: December 8, 2020Assignee: THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATIONInventors: Anat Elmann, Rivka Ofir
-
Patent number: 10857193Abstract: Cactus pear (Opuntia) extract compositions, their methods of preparation, and their uses in products are provided. The Opuntia extract compositions are a mixture of an extract prepared by extraction of Opuntia fruit/fruit parts, combined with an extract prepared by extraction of Opuntia cladodes/cladode parts. The resulting Opuntia extract compositions exhibit improved therapeutic characteristics as compared with known Opuntia fruit juices or extracts, including increased hypoglycemic effects.Type: GrantFiled: November 6, 2008Date of Patent: December 8, 2020Assignee: FINZELBERG GMBH & CO. KGInventors: Ivo Pischel, Bjoern Feistel, Bernd Walbroel
-
Patent number: 10857194Abstract: A hybrid herbal and drug composition includes an amount of Chinese herb about 0.01 to 5% by weight of the composition; an amount of animal-based matter about 0.01 to 5% by weight of the composition; an amount of vitamin about 0.01 to 5% by weight of the composition; an amount of mineral about 0.01 to 5% by weight of the composition; an amount of hormone about 0.01 to 5% by weight of the composition; an amount of factory produced product about 0.01 to 5% by weight of the composition; and an amount of the purified water about 70% to 99.94% by weight of the composition.Type: GrantFiled: February 14, 2019Date of Patent: December 8, 2020Inventor: Shui Yin Lo
-
Patent number: 10857195Abstract: Extracts of plants of the Lamiaceae family, including the Mentha genus, are shown to have a positive impact on overall cognitive health, including improvements in memory, reasoning, attention/concentration, planning, mood, sleep and associated behaviors.Type: GrantFiled: September 15, 2015Date of Patent: December 8, 2020Assignee: KEMIN INDUSTRIES, INC.Inventors: Michael Ceddia, Kelli Herrlinger, Brandon Lewis, Shulin Feng, Kristin Nieman
-
Patent number: 10857196Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.Type: GrantFiled: April 27, 2018Date of Patent: December 8, 2020Assignee: BicycleTx LimitedInventors: Paul John Beswick, Gabriela Ivanova-Berndt, Gemma Elizabeth Mudd, Silvia Pavan, Michael Skynner, Daniel Paul Teufel, Katerine Van Rietschoten
-
Patent number: 10857197Abstract: Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.Type: GrantFiled: December 14, 2015Date of Patent: December 8, 2020Assignee: THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCHInventors: Kevin J. Tracey, Huan Yang, Yousef Al-Abed
-
Patent number: 10857198Abstract: The invention relates to cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection. In particular, the invention provides a cyclosporine liquid formulation for use as an aerosol for inhalation in a method of preventing or treating pulmonarychronic graft rejection in single lung transplanted patients. The formulation is preferably administered once or twice daily. The formulation may be aerosolized with a nebulizer that comprises features for monitoring the time, date and duration of inhalation by the patient, in order to monitor patient adherence. The formulation according to the invention may be combined with standard immunosuppressants and corticosteroids.Type: GrantFiled: March 15, 2016Date of Patent: December 8, 2020Assignee: BREATH THERAPEUTICS GMBHInventors: Martin Knoch, Oliver Denk
-
Patent number: 10857199Abstract: A method of promoting hair growth can include: a polypeptide having a sequence that has at least 75% complementarity to or at least 75% identical to SPR4; and topically administering the polypeptide to a subject. This can include putting or causing the polypeptide to be in the skin, such as in any dermal layer. In one aspect, the method can include administering the composition topically so as to administer the polypeptide to the subject. In one aspect, the method can include administering the polypeptide to skin of the subject. In one aspect, the method can include administering the polypeptide to a hair follicle of the subject. In one aspect, the method can include administering the polypeptide to a bald spot of the subject.Type: GrantFiled: June 18, 2019Date of Patent: December 8, 2020Assignee: The University of KansasInventors: Peter S. N. Rowe, Aline Martin, Nicolae Valentin David, M. Laird Forrest, Kenneth Ryan Moulder, Shuang Cai, Daniel J. Aires
-
Patent number: 10857200Abstract: This invention relates, in part, to methods and compositions that are useful for the treatment and/or prevention of various disorders, including radiation-related disorders, such as acute radiation syndrome.Type: GrantFiled: November 21, 2018Date of Patent: December 8, 2020Assignee: Cleveland BioLabs, Inc.Inventors: Vadim Krivokrysenko, Elena Feinstein
-
Patent number: 10857201Abstract: Neonatal NET-Inhibitory Factor (nNIF) and nNIF-Related Peptides (NRPs) are provided. Methods for the treatment of and prophylaxis against inflammatory disorders and cancer are also provided. Additionally, methods for the inhibition of metastasis in patients having cancer are provided. The methods can include administering nNIF and/or a NRP to patients having, or at risk of developing, an inflammatory disorder or a cancer.Type: GrantFiled: September 5, 2017Date of Patent: December 8, 2020Assignee: Ballard Spahr LLPInventors: Christian Con Yost, Guy A. Zimmerman, Andrew S. Weyrich, Joshua Schiffman
-
Patent number: 10857202Abstract: The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits the ligand of Uniprot # P05112 and/or the ligand of Uniprot # P35225 from binding to their respective receptors to a subject in need thereof. In some embodiments, the disorder is preferably associated with an increase of the Th2 immune response. In some embodiments, administration is preferably locally to the lung in order to treat, ameliorate or prevent allergic asthma, rhinitis, conjunctivitis, lung fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, pulmonary alveolar proteinosis or adult respiratory distress syndrome.Type: GrantFiled: July 16, 2019Date of Patent: December 8, 2020Inventors: Andreas Hohlbaum, Laurent Audoly, Beverly Koller
-
Patent number: 10857203Abstract: Disclosed herein are compositions comprising non-naturally occurring zinc finger domains, fusion proteins comprising these zinc finger domains, polynucleotides encoding these proteins, cells expressing these proteins and pharmaceutical compositions comprising these proteins or polynucleotides as well as methods of modifying an Htt gene using these compositions for treating or preventing Huntington's Disease.Type: GrantFiled: September 30, 2019Date of Patent: December 8, 2020Assignee: Sangamo Therapeutics, Inc.Inventors: Jeffrey C. Miller, Edward J. Rebar, H. Steve Zhang
-
Patent number: 10857204Abstract: The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl l, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ?-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.Type: GrantFiled: May 2, 2019Date of Patent: December 8, 2020Assignee: TerSera Therapeutics LLCInventors: David J. Ellis, George P. Miljanich, David E. Shields
-
Patent number: 10857205Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.Type: GrantFiled: August 6, 2018Date of Patent: December 8, 2020Assignee: Regeneron Pharmaceuticals, Inc.Inventor: George D. Yancopoulos
-
Patent number: 10857206Abstract: A method of preventing or treating cutaneous pigmentation disease in a subject in need thereof, includes: providing a pharmaceutical composition comprising SDF1, an inducer or activator of SDF1, as an active ingredient; and administering the pharmaceutical composition to the subject, wherein the cutaneous pigmentation is prevented or treated, and the cutaneous pigmentation disease is selected from the group consisting of melasma, freckles, lentigo, nevus, pigmentation by drugs, pigmentation after inflammation and hyperpigmentation incurred from dermatitis.Type: GrantFiled: October 30, 2018Date of Patent: December 8, 2020Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Hee Young Kang, Tae Jun Park, Jung Eun Yoon, Mi Sun Kim
-
Patent number: 10857207Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.Type: GrantFiled: March 2, 2018Date of Patent: December 8, 2020Assignee: MannKind CorporationInventors: Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
-
Patent number: 10857208Abstract: Described herein are methods and compositions for inducing melanogenesis in a human subject. The method comprises administering to a subject an alpha-MSH analogue, in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of subject without inducing homologous desensitization of the melanocortin-1 receptors.Type: GrantFiled: August 27, 2018Date of Patent: December 8, 2020Assignee: CLINUVEL PHARMACEUTICALS LIMITEDInventors: Michael John Kleinig, Thomas R. Tice, Jay K. Staas
-
Patent number: 10857209Abstract: Methods of cancer treatment are disclosed. Particularly, disclosed herein are methods of administering LAL and PPAR? ligands for treating various cancer patients to promote anti-cancer immunity (suppress MDSC), use for inhibiting tumor progression, and use for inhibiting tumor metastasis.Type: GrantFiled: February 10, 2017Date of Patent: December 8, 2020Assignee: Indiana University Research and Technology CorporationInventors: Cong Yan, Hong Du
-
Patent number: 10857210Abstract: Compositions and methods to promote wound healing are described. The compositions and methods up-regulate X-box binding protein 1 (XBP1) and/or inositol-requiring enzyme-1 (IRE-1). In various embodiments, the compositions and methods can be used to promote wound healing in diabetic subjects.Type: GrantFiled: July 6, 2016Date of Patent: December 8, 2020Assignee: Wayne State UniversityInventors: Kezhong Zhang, Jiemei Wang
-
Patent number: 10857211Abstract: Markers for genomic instability in Fanconi Anemia (FA) and other pathologies for therapeutic and diagnostic uses. In one embodiment, glycosphingolipid metabolism is altered in the FA deficient squamous cell carcinoma (SCC) cells, based on analysis of a metabolomics/lipidomics platform. The data indicated ganglioside metabolism was important in FA patients' susceptibility to SCC progression.Type: GrantFiled: November 22, 2016Date of Patent: December 8, 2020Assignee: CHILDREN'S HOSPITAL MEDICAL CENTERInventors: Susanne I. Wells, Kenneth D. R. Setchell, Lindsey Romick-Rosendale, Wujuan Zhang, Xueheng Zhao
-
Patent number: 10857212Abstract: A method for treating Pompe disease including administration of recombinant human acid ?-glucosidase having optimal glycosylation with mannose-6-phosphate residues in combination with an amount of miglustat effective to maximize tissue uptake of recombinant human acid ?-glucosidase while minimizing inhibition of the enzymatic activity of the recombinant human acid ?-glucosidase is provided.Type: GrantFiled: April 11, 2018Date of Patent: December 8, 2020Assignee: Amicus Therapeutics, Inc.Inventors: Hung V. Do, Richie Khanna, Russell Gotschall